BNTC
Benitec Biopharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.68
+1.93%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -66.5%
- EBIT
- -52.9%
- EPS
- +35.5%
- Free cash flow
- -10.2%
- Operating cash flow
- -10.2%
Forward estimates
Based on analyst estimates
- Revenue
- +6446.8%
- EBITDA
- +80.2%
- EPS
- +27.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -86.8%
- EBIT
- -85.7%
- Net income
- -74.3%
- EPS
- +60.8%
- Free cash flow
- -20.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026